Boron neutron capture therapy for glioblastoma: improvement of boron biodistribution by hyaluronidase.
Boron neutron capture therapy (BNCT) represents a highly promising therapeutic alternative for the treatment of the most common malignant brain tumor, glioblastoma multiforme. Both the efficacy and safety of BNCT are greatly dependent on the pattern of 10B biodistribution. The present study investigates the influence of systemic hyaluronidase applied in combination with Na2B12H11SH (BSH), a boron carrier used in current clinical trials. The application of hyaluronidase was associated with a statistically significant improvement in the tumor/blood boron concentration ratio which suggests that hyaluronidase is capable of enhancing the therapeutic potential of BSH.
Haselsberger
K
K
Department of Neurosurgery, Karl-Franzens University, Graz, Austria.
Radner
H
H
Pendl
G
G
D001895:Boron / Q000493:pharmacokinetics*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use*; D017247:Neutron Capture Therapy; D014018:Tissue Distribution
D006821:Hyaluronoglucosaminidase; D001895:Boron